Fingolimod for the treatment of relapsing multiple sclerosis

ISSN： 1473-7175

Source： Expert Review of Neurotherapeutics, Vol.13, Iss.6, 2013-06, pp. : 589-602

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Fingolimod for relapsing multiple sclerosis: an update

By Horga Alejandro Castilló Joaquín Montalban Xavier

Expert Opinion on Pharmacotherapy, Vol. 11, Iss. 7, 2010-05 ,pp. : 1183-1196

Informa Healthcare

Access to resources Recommend Favorite

Fingolimod: A Review of its Use in the Management of Relapsing-Remitting Multiple Sclerosis

By Scott Lesley J.

CNS Drugs, Vol. 25, Iss. 8, 2011-08 ,pp. : 673-698

Adis International

Access to resources Recommend Favorite

Pharmacokinetic evaluation of fingolimod for the treatment of multiple sclerosis

By Tanasescu Radu Constantinescu Cris S

Expert Opinion on Drug Metabolism and Toxicology, Vol. 10, Iss. 4, 2014-04 ,pp. : 621-630

Informa Healthcare

Access to resources Recommend Favorite

Determination of Seminal Concentration of Fingolimod and Fingolimod‐Phosphate in Multiple Sclerosis Patients Receiving Chronic Treatment With Fingolimod

Clinical Pharmacology In Drug Development, Vol. 7, Iss. 2, 2018-02 ,pp. : 217-221

John Wiley & Sons Inc

Access to resources Recommend Favorite

Cladribine tablets for the treatment of relapsing–remitting multiple sclerosis

By Comi Giancarlo Hartung Hans-Peter Kurukulasuriya Nuwan C Greenberg Steven J Scaramozza Matthew

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 1, 2013-01 ,pp. : 123-136

Informa Healthcare

Access to resources Recommend Favorite